TNF-α antagonist infliximab in the treatment of depression in older adults: Results of a prematurely ended, randomized, placebo-controlled trial

Journal of Clinical Psychopharmacology

Volumn 30, Issue 3, 2010, Pages 343-345

  Maas, D Willemijn ^a   Westendorp, Rudi G J ^a   Willems, Jorien M ^a   De Craen, Anton J M ^a   Van Der Mast, Rose C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); CITALOPRAM; FLUOXETINE; INFLIXIMAB; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; PLACEBO; SERTRALINE; TRAZODONE; VENLAFAXINE;

AGED; AGING; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DYSTHYMIA; FEMALE; HUMAN; LETTER; LOW DRUG DOSE; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; ONSET AGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; REMISSION; SLURRED SPEECH; STRESS;

AGE FACTORS; AGED; ANTIBODIES, MONOCLONAL; DEPRESSIVE DISORDER; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PILOT PROJECTS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77952368632     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181dcf0de     Document Type: Letter

References (12)

1. Beekman AT, Copeland JR, Prince MJ. Review of community prevalence of depression in later life. Br J Psychiatry. 1999;174:307-311.
2. Jongenelis K, Pot AM, Eisses AM, et al. Prevalence and risk indicators of depression in elderly nursing home patients: the AGED study. J Affect Disord. 2004;83:135-142.
3. Devanand DP, Adorno E, Cheng J, et al. Late-onset dysthymic disorder and major depression differ from early onset dysthymic disorder and major depression in elderly outpatients. J Affect Disord. 2004;78:259-267.
4. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med. 2008;358:55-68.
5. Alexopoulos GS, Meyers BS, Young RC, et al. 'Vascular depression' hypothesis. Arch Gen Psychiatry. 1997;54:915-922.
6. Smith RS. The macrophage theory of depression. Med Hypotheses. 1991;35: 298-306.
7. Irwin MR, Miller AH. Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun. 2007; 21:374-383.
8. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27:24-31.
9. Craddock D, Thomas A. Cytokines and late-life depression. Essent Psychopharmacol. 2006;7:42-52.
10. Eikelenboom P, Hoogendijk WJ, Jonker C, et al. Immunological mechanisms and the spectrum of psychiatric syndromes in Alzheimer's disease. J Psychiatr Res. 2002;36:269-280.
11. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006;367:29-35.
12. Mody L, Miller DK, McGloin JM, et al. Recruitment and retention of older adults in aging research. JAGS. 2008;56:2340-2348.